课题基金 / 基金详情

Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosis

Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosis
定义囊性纤维化肺部恶化治疗终点的生物标志物
批准号:
nhmrc : GNT1126973
负责人:
A/Pr Robert Trengove
金额:
$103.14万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2017
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2017-01-01 至 --

项目摘要

项目成果

A/Pr Robert Trengove的其他基金

相似基金

相关文献

中文摘要
翻译
需要敏感和可靠的测试来监测囊性纤维化的肺部疾病严重程度。近年来出现了一些潜在的方法。我们将研究这些测试如何跟踪肺部疾病的急性发作,并确定在典型的治疗过程后,是否有残留损伤的证据有助于肺部疾病的整体进展。
英文摘要
Sensitive and reliable tests are required to monitor lung disease severity in cystic fibrosis. A number of potential methods have emerged in recent years. We will investigate how these tests track an acute episode of lung disease and determine whether, following a typical course of treatment, there is evidence of residual damage that contributes to overall progression of lung disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Predicting the long term lung health outcomes in young adults born very preterm
  • 批准号:
    nhmrc : GNT1138605
  • 项目类别:
    Project Grants
  • 资助金额:
    $85.42万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Robert Trengove
  • 依托单位:
Predicting the long term lung health outcomes in young adults born very preterm
  • 批准号:
    nhmrc : 1138605
  • 项目类别:
    Project Grants
  • 资助金额:
    $57.76万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Robert Trengove
  • 依托单位:
Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosis
  • 批准号:
    nhmrc : 1126973
  • 项目类别:
    Project Grants
  • 资助金额:
    $70.5万
  • 财政年份:
    2017
  • 负责人:
    A/Pr Robert Trengove
  • 依托单位:
海外基金